Multiple phase I-II trials of PD-1/PD-L1 plus EGFR inhibitors in R/M HNSCC are complete [Table 5]; an ongoing phase III trial assesses cetuximab/radiotherapy with avelumab in locally advanced HNSCC[146]. Here, EGFR is linked to head and neck squamous cell carcinoma.